Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekljudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, von Minckwitz G, Buyse M, Piccart M.
Michiels S, et al. Among authors: cobleigh m.
Ann Oncol. 2016 Jun;27(6):1029-1034. doi: 10.1093/annonc/mdw132. Epub 2016 Mar 8.
Ann Oncol. 2016.
PMID: 26961151
Free article.